DK0970084T3 - Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase - Google Patents

Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase

Info

Publication number
DK0970084T3
DK0970084T3 DK98913690T DK98913690T DK0970084T3 DK 0970084 T3 DK0970084 T3 DK 0970084T3 DK 98913690 T DK98913690 T DK 98913690T DK 98913690 T DK98913690 T DK 98913690T DK 0970084 T3 DK0970084 T3 DK 0970084T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
group
phenyl
alkyl group
formula
Prior art date
Application number
DK98913690T
Other languages
Danish (da)
English (en)
Inventor
David John Calderwood
David Norman Johnston
Paul Rafferty
Helen Louise Twigger
Rainer Munschauer
Lee Arnold
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of DK0970084T3 publication Critical patent/DK0970084T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98913690T 1997-03-19 1998-03-09 Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase DK0970084T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4083697P 1997-03-19 1997-03-19
PCT/EP1998/001357 WO1998041525A1 (en) 1997-03-19 1998-03-09 Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DK0970084T3 true DK0970084T3 (da) 2003-09-29

Family

ID=21913242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98913690T DK0970084T3 (da) 1997-03-19 1998-03-09 Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase

Country Status (23)

Country Link
US (1) US6001839A (id)
EP (1) EP0970084B1 (id)
JP (1) JP2001516353A (id)
KR (1) KR20000076426A (id)
CN (1) CN1134439C (id)
AT (1) ATE242245T1 (id)
AU (1) AU748884B2 (id)
BG (1) BG64282B1 (id)
BR (1) BR9808281A (id)
CA (1) CA2283961A1 (id)
DE (1) DE69815317T2 (id)
DK (1) DK0970084T3 (id)
ES (1) ES2202827T3 (id)
HU (1) HUP0001507A3 (id)
ID (1) ID24653A (id)
IL (1) IL131582A0 (id)
NO (1) NO313962B1 (id)
NZ (1) NZ337529A (id)
PL (1) PL335685A1 (id)
PT (1) PT970084E (id)
SK (1) SK125999A3 (id)
TR (1) TR199902301T2 (id)
WO (1) WO1998041525A1 (id)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO2000012089A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
PL354241A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US7369946B2 (en) 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
MXPA02009543A (es) * 2000-03-29 2005-08-26 Abbott Gmbh & Co Kg Metodo para identificar inhibidores de tie-2.
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
KR100403860B1 (ko) * 2000-12-27 2003-11-01 엘지전자 주식회사 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
KR100875380B1 (ko) * 2001-06-23 2008-12-23 아벤티스 파마슈티칼스 인크. 단백질 키나제 억제제로서의 피롤로피리미딘
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
US20040259892A1 (en) * 2001-06-29 2004-12-23 Alain Moussy Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
EP1401411A2 (en) * 2001-06-29 2004-03-31 AB Science Use of tyrosine kinase inhibitors for treating bone loss
JP2004537536A (ja) 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
DE60215648T2 (de) 2001-06-29 2007-08-23 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
GB0302748D0 (en) * 2003-02-06 2003-03-12 Novartis Ag Organic compounds
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1620094A4 (en) * 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
MXPA06013805A (es) * 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
RU2007138264A (ru) * 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
ZA200802685B (en) * 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
EP2385053B1 (en) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
WO2007087441A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
US7659274B2 (en) * 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
EP1969934A1 (de) * 2007-03-12 2008-09-17 Bayer CropScience AG 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009117482A1 (en) * 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc Mtor inhibitor salt forms
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
ES2581848T3 (es) * 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166413A2 (en) * 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103333096A (zh) * 2013-06-25 2013-10-02 苏州大学 一种化学选择性制备多功能吡咯衍生物的新方法
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3334430B1 (en) * 2015-08-13 2025-02-26 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3472165B1 (en) 2016-06-21 2023-09-06 Nerviano Medical Sciences S.r.l. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
PL4039675T3 (pl) 2017-04-18 2025-01-07 Eli Lilly And Company Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe
MA52954A (fr) 2018-06-21 2021-04-28 Cellestia Biotech Ag Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
JP2021535113A (ja) * 2018-08-22 2021-12-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. ピロロ−アミノ−ピリダジノン化合物およびその中間体の調製方法
CA3134791A1 (en) * 2019-04-10 2020-10-15 Cellestia Biotech Ag Inhibitors of notch signalling pathway and use thereof in treatment of cancers
AU2020274083B9 (en) * 2019-05-13 2025-05-01 D.E. Shaw Research, Llc FGFR inhibitors and methods of use thereof
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
US20220356186A1 (en) * 2019-08-29 2022-11-10 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
EP4021893A1 (en) 2019-08-29 2022-07-06 Hibercell, Inc. Perk inhibiting compounds
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
KR20240075952A (ko) * 2021-09-23 2024-05-30 3에이치 파머슈티컬즈 컴퍼니 리미티드 Fgfr 억제제 및 이의 사용 방법
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
CN118369322A (zh) * 2021-12-06 2024-07-19 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物，其制法与医药上的用途
CN116903628A (zh) * 2022-04-20 2023-10-20 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501532A (ja) * 1994-06-09 1998-02-10 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) * 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
ES2203793T3 (es) * 1996-03-15 2004-04-16 Novartis Ag N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.

Also Published As

Publication number Publication date
CA2283961A1 (en) 1998-09-24
NO994509L (no) 1999-09-17
AU6829398A (en) 1998-10-12
US6001839A (en) 1999-12-14
HUP0001507A3 (en) 2002-01-28
HUP0001507A2 (hu) 2000-10-28
ES2202827T3 (es) 2004-04-01
PL335685A1 (en) 2000-05-08
NO994509D0 (no) 1999-09-17
BR9808281A (pt) 2000-05-16
NO313962B1 (no) 2003-01-06
JP2001516353A (ja) 2001-09-25
CN1134439C (zh) 2004-01-14
ATE242245T1 (de) 2003-06-15
NZ337529A (en) 2000-10-27
BG103785A (en) 2000-06-30
EP0970084A1 (en) 2000-01-12
SK125999A3 (en) 2000-05-16
KR20000076426A (ko) 2000-12-26
EP0970084B1 (en) 2003-06-04
TR199902301T2 (xx) 1999-12-21
DE69815317T2 (de) 2005-04-07
PT970084E (pt) 2003-10-31
IL131582A0 (en) 2001-01-28
BG64282B1 (bg) 2004-08-31
ID24653A (id) 2000-07-27
WO1998041525A1 (en) 1998-09-24
DE69815317D1 (de) 2003-07-10
CN1259950A (zh) 2000-07-12
AU748884B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
DK0970084T3 (da) Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
ATE391719T1 (de) Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
TW221434B (id)
YU73300A (sh) Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
MX9203249A (es) Derivados del acido bencimidazolin-2-oxo-1-carboxilico y composiciones farmaceuticas que los contienen.
DK0566199T3 (da) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoler og deres anvendelse som antivirale midler
ES8401073A1 (es) Un procedimiento para la preparacion de nuevos derivados de 3-triazolo (4,5-b) 1,5) benzodiazpezina.
IL91541A0 (en) Aryloxy-,arylthio-,heteroaryloxy-,and heteroarylthioalkenylene derivatives of amines,their preparation and pharmaceutical compositions containing them
MY118844A (en) 2,4,4-trisubstituted-1,3-dioxolane antifungals
AR035525A1 (es) Compuestos utiles como agentes antifungicos, composicion farmaceutica, usos de los compuestos y proceso para prepararlos
ES2026452T3 (es) Un procedimiento para preparar 6h-isoxazolo/ 3,4-d/pirazolo/3,4-b/piridinas.
AR025436A1 (es) Compuestos de 4,5-diariloxazol, procesos para prepararlos, las composiciones farmaceuticas que las contienen, su preparacion y el uso de tales compuestoscomo agonistas de prostaglandina i2.